Pliant Therapeutics
PLRX· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock -90.7% in FY2025
Bernard Coulie, M.D., Ph.D., M.B.A. is the CEO of Pliant Therapeutics and was paid $5.5M in FY2025 (Dec), down 17%.
Pay$100 in the stock at the end of FY20 → $5
Executives4
See all- 1Bernard Coulie, M.D., Ph.D., M.B.A.President, Chief Executive Officer and DirectorFY2025
- 2Éric Lefebvre, M.D.Former Chief Medical OfficerFY2025
- 3Keith Cummings, M.D., M.B.A.Chief Financial OfficerFY2025
- 4Minnie KuoChief Operating OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allPliant Therapeutics paid its 4 named executives $12.1M in total in FY2025 (Dec). CEO Bernard Coulie, M.D., Ph.D., M.B.A. was paid $5.5M of that.
| Name | |||
|---|---|---|---|
| Bernard Coulie, M.D., Ph.D., M.B.A.President, Chief Executive Officer and Director | |||
| Éric Lefebvre, M.D.Former Chief Medical Officer | |||
| Keith Cummings, M.D., M.B.A.Chief Financial Officer | |||
| Minnie KuoChief Operating Officer | Not disclosed | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Pliant Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 22, 2026 | FY2025 |
| Annual report | 10-K | Mar 11, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 23, 2025 | FY2024 |
| Annual report | 10-K | Mar 3, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 22, 2024 | FY2023 |
| Annual report | 10-K | Feb 27, 2024 | FY2023 |
